Adding the IDO-pathway inhibitor indoximod to pembrolizumab improved the melanoma response rate
Adding the investigational immunotherapy indoximod to the FDA-approved immunotherapy pembrolizumab (Keytruda) increased the proportion of patients with advanced melanoma who responded to treatment compared with previously ...
Apr 5, 2017
0
0